Pictor raises $7.5M bridge round to scale proteomic platform
What's the deal? Pictor, a Carlsbad, California-based targeted proteomic platform company, has closed a $7.5 million convertible bridge round backed by existing investors.
The financing brings Pictor's total capital raised to roughly $30 million. It will fund commercial partnerships, platform and manufacturing scale-up, and translational studies across human and animal health markets.
Why now? The round follows a strong first year at Pictor's US headquarters, where it launched seven commercial products and secured four strategic partnerships.
It also recently appointed Terry Kelly as chief operating officer and Tim Shannon as chief financial officer. The bridge strengthens its position as it evaluates a US-based Series A.
Pictor's platform — comprising PictArray, PictImager, and Pictorial software — lets laboratories analyse up to 20 protein targets from a single sample in under two hours.
The system aims to cut cost and workflow complexity across pharma, reference laboratory, and animal health markets.
What could go wrong? Pictor expects to enter licensing stages with multiple partners within 12 to 18 months — a timeline that hinges on adoption gaining momentum.
A bridge round also signals the company is buying time before a larger raise. Whether the planned Series A materialises depends on continued commercial traction.
The signal: Pictor's existing investors doubling down via a bridge — rather than a priced round — reflects a cautious diagnostics funding climate where breakout-stage companies are stretching runway toward proof points before testing the market for a US Series A. With seven products and four partnerships already live, the multiplexed proteomics player is positioning commercial traction, not just technology, as the case for its next raise.
Read more: Finanznachrichten
Image credit: Generated with Gemini
